Back to search results

Immunotherapy and Irreversible Electroporation for Advanced Pancreatic Cancer

This study is looking at a new way to treat advanced pancreatic cancer by combining two treatments: Irreversible Electroporation (a procedure that uses electrical pulses to destroy tumor cells) and Nivolumab (an immunotherapy drug that helps your body's immune system fight cancer). You might be able to join if you are at least 18 years old, have stage III pancreatic cancer, and meet other health requirements. The main goal is to see how safe and tolerable this combination treatment is. The study plans to enroll 10 participants, but its current recruitment status is unclear.

Study design
This is a Phase II study involving 10 participants. All participants will receive Irreversible Electroporation followed by Nivolumab.
What's involved
Participants will receive Nivolumab every two weeks for a total of 4 doses after their Irreversible Electroporation procedure.
Compensation
Not stated in the trial record.
Follow-up
Your safety and how well you tolerate the treatment will be checked from the start of the study until 100 days after your last dose of Nivolumab.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03080974

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Recruiting
PHASE2Ages 18+InterventionalTreatment
University of Louisville
~10 participants
Updated 2025-10-29 on ClinicalTrials.gov
What's tested:NivolumabIrreversible Electroporation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Tolerability of Combination Irreversible Electroporation and Nivolumab Treatment
Measured over Baseline thru 100 days after receiving last dose

Conditions

Pancreatic Adenocarcinoma

Explore related trials

Pancreatic Adenocarcinoma

NCT03080974

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Louisville

    Louisville, Kentuckyno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Robert Martin, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Louisville

Who to contact

Robert Martin, MD, PhD
[email protected]
502-629-3355
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

≥ 18 years if age
Diagnosed with stage III pancreatic cancer
Tumor is measurable
Glomerular Filtration Rate \> 60 m/L/min/1.73 m(2)
Willing and able to comply with the protocol requirements
Able to comprehend and have signed the informed consent to participate

Exclusion

Participating in another clinical trial for the treatment of cancer at time of screening
Are pregnant or currently breast feeding
Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure
Have non-removable implants with metal parts within 1 cm of the target lesion
Had a myocardial infarction within 3 months prior to enrollment

What this trial measures

  • Safety and Tolerability of Combination Irreversible Electroporation and Nivolumab TreatmentBaseline thru 100 days after receiving last dose

    Adverse events and Serious adverse events will be collected